Pharmaceutical firm Strides Arcolab today said it has received the UK health regulator's approval for its antibiotics manufacturing facility in Brazil.
The company has received certificate of GMP compliance from the UK-based Medicines and Healthcare products Regulatory Agency (MHRA) for its manufacturing site at Campos, Brazil, for its dedicated sterile products, Strides Arcolab said in a statement.
The Campos unit is a dedicated facility that produces a specific type of antibiotics called carbapenems.
"This approval is an important milestone and shall significantly enhance our business opportunities in the European region for a niche group of products," Strides Arcolab Executive Director V S Iyer said.
Strides acquired the Campos facility from South African pharma company Aspen and is in the process of getting hold of its ownership, it said.
The facility also manufactures penicillins for the Latin American markets and has already received approval from National Health Surveillance Agency (ANVISA), Brazil, it added.
Shares of Strides Arcolab rose 2.35 per cent to hit an all time high of Rs 456 on the Bombay Stock Exchange in afternoon trade.
